share_log
Breakings ·  Dec 20, 2024 22:26
Synaptogenix Inc: Delivery of a Termination Notice Pursuant to Its Agreement to Conduct a Phase 1 Trial of Bryostatin-1 in Multiple Sclerosis
The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.
    Write a comment